$10.15
2.68% yesterday
Nasdaq, Nov 17, 10:00 pm CET
ISIN
US65343E1082
Symbol
NXTC

NextCure, Inc. Stock price

$10.15
-1.79 14.96% 1M
+4.75 87.87% 6M
+0.89 9.65% YTD
-5.34 34.46% 1Y
-7.50 42.49% 3Y
-110.34 91.58% 5Y
-169.86 94.36% 10Y
-169.86 94.36% 20Y
Nasdaq, Closing price Mon, Nov 17 2025
+0.27 2.68%
ISIN
US65343E1082
Symbol
NXTC
Industry

Key metrics

Basic
Market capitalization
$27.2m
Enterprise Value
$-1.9m
Net debt
positive
Cash
$29.1m
Shares outstanding
2.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.0
P/B
1.2
Financial Health
Equity Ratio
81.0%
Return on Equity
-85.5%
ROCE
-210.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-57.8m | -
EBIT
$-60.3m | $-62.4m
Net Income
$-58.0m | $-48.8m
Free Cash Flow
$-48.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
2.4% | -
EBIT
3.2% | -8.6%
Net Income
0.0% | 12.9%
Free Cash Flow
-8.7%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-21.7
FCF per Share
$-18.3
Short interest
1.2%
Employees
43
Rev per Employee
$0.0
Show more

Is NextCure, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.

NextCure, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a NextCure, Inc. forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a NextCure, Inc. forecast:

Buy
78%
Hold
22%

Financial data from NextCure, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 13 13
18% 18%
-
- Research and Development Expense 46 46
3% 3%
-
-58 -58
2% 2%
-
- Depreciation and Amortization 2.49 2.49
18% 18%
-
EBIT (Operating Income) EBIT -60 -60
3% 3%
-
Net Profit -58 -58
0% 0%
-

In millions USD.

Don't miss a Thing! We will send you all news about NextCure, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NextCure, Inc. Stock News

Neutral
GlobeNewsWire
about 21 hours ago
BELTSVILLE, Md., Nov. 17, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today announced the closing of its previously announced private placement in public equity (“PIPE”). The PIPE was led by Ikarian Capital, Squadron Capital Management, Affinity Healthcare Fund, LP, and Exome Asset Ma...
Neutral
GlobeNewsWire
6 days ago
BELTSVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today announced that it has entered into definitive agreements with the participation of certain institutional and accredited investors, including Ikarian Capital, Squadron Capital Management, Affinity Healthcare Fu...
Neutral
GlobeNewsWire
13 days ago
BELTSVILLE, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) --  NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported third quarter 2025 financial results.
More NextCure, Inc. News

Company Profile

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.

Head office United States
CEO Michael Richman
Employees 43
Founded 2015
Website www.nextcure.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today